Intranasal Heparin Tolerability Study

• Sponsor: Joshua Sharp (Other)
• Overall Status: Completed
• CT.gov ID: NCT04490239
• Collaborator: (none)
• Enrollment: 6
• Location: 1
• Arm: 1
• Actual Duration (Months): 1.3
• Patients Per Site Per Month: 4.6

Study Details

Study Description

Brief Summary

The investigators are investigating the tolerability of Heparin Sodium (porcine) administered topically via a nasal spray. This agent is being investigated as a potential prophylactic treatment to prevent infection by SARS(severe acute respiratory syndrome)-CoV-2, the novel coronavirus that causes COVID-19. Heparin Sodium (porcine) is an FDA-approved anticoagulant drug administered by injection. Recent work from multiple groups have found that heparin can prevent the infection of cells by SARS-CoV-2, indicating a possible use as a topical anti-viral. Numerous studies in both rodent models and humans have shown that heparin administered via a pulmonary or intranasal route enters the blood stream in negligible amounts, suggesting intranasal administration of heparin should be safe even at very large doses. Data from mouse models indicate that repeated daily nasal administration of heparin had no adverse effects in mice over a two week period (including weight loss, nose bleeds, loss of sense of smell, nasal discharge, or decreased blood clotting time). However, no data of repeated nasal administration of heparin in humans is available.

The investigators will test nasal administration of FDA-approved heparin sodium (porcine), originally formulated for injection. The formulations the investigators will be testing consist of heparin, sodium chloride, and 1% benzyl alcohol as a preservative bottled in a nasal sprayer dispensing 0.1 mL(millilitres) per spray. The investigation is planned in two phases. A single-dose phase will test the acute tolerability of the drug. In this phase, subjects will be administered 0.1 mL of Heparin Sodium in each nostril formulated at one of two doses: Day 1 will test a formulation of 5000 U(units)/mL, and Day 2 will test a formulation of 10000 U(units) /mL. After each dose, subjects will be tested for systemic exposure via blood aPTT tests and platelet count, as well as for local topical toxicity via examination for epistaxis and anosmia, along with any other adverse events. In the chronic phase, subjects will be administered the highest dose that was tolerated in the acute phase daily for fourteen days. Subjects will be tested for aPTT and platelet count, as well as epistaxis, anosmia and any other adverse events.

Condition or Disease	Intervention/Treatment	Phase
Covid19	Drug: Intranasal heparin sodium (porcine)	Early Phase 1

Detailed Description

Study Objectives

This exploratory clinical trial is designed to assess tolerability of increasing doses of intranasally administered heparin sodium in saline solution. Baseline values for aPTT and complete blood count will be obtained from six subjects. Heparin will be administered in increasing concentrations using one 0.1 mL(millilitre) spray per nostril (0.2 ml total) on a daily basis. Major signs of toxicity will be clinically relevant changes in aPTT time, clinically relevant decrease in platelet count, signs of anosmia 30 minutes after administration, or epistaxis. Dosing will start at 1000 units of heparin administered (500 units in each nostril) and then escalated to 2000 units. Should a clinically relevant aPTT prolongation (>50% increase from subject baseline) or decrease in platelet count (below clinical lab normal limit) be observed at either dose, the study will be halted and a series of lower doses evaluated.

Study Overview

Description of Design of Study

This study is a single center, prospective, Phase 0 exploratory tolerability trial. A total of 6 healthy subjects (3 M and 3 F) will be enrolled into the study. This study will evaluate the acute and multi-day (14 days) tolerability of intranasally administered heparin.

Test Article

Investigational Product

The study will assess the single and multi-dose tolerability of intranasal administration of an aliquot of an FDA-approved heparin sodium injection (5,000 USP units/mL or 10,000 USP units/mL) to deliver 1000U (units) or 2000U of heparin sodium. Doses will be prepared and administered as follows:

1000 U = (2 x 0.1 mL(milliliter) of 5000U(units)/mL or one spray of 500 U in each nostril) 2000 U = (2 x 0.1 mL of 10000U/mL or one spray of 1000 U in each nostril)

The test article will be administered by transferring (4 mL) of sterile heparin sodium injection (5,000 USP units/mL or 10,000 USP units/mL) at ambient room temperature into intranasal spray bottles, one for each individual subject.

The test article will be administered within 4 weeks of preparation, and the remainder discarded after study completion.

Supplier The test article (Heparin Sodium USP) will be obtained from appropriate commercial sources.

Safety Assessments

Safety assessments will be completed as part of this single and multi-dose, pharmacokinetic study. Safety will be assessed prior to test article administration and at 24 post dose, in the acute phase. For safety assessments during the chronic phase, safety assessments will be assessed prior to test article administration , day 14 and day 15-post study. Test subject will be called every three (3) days for updates and subjective reports (adverse events), during 14 day, daily dose phase. Subject safety will be assessed by monitoring adverse events, clinical laboratory tests, vital signs, and physical examinations.

Laboratory parameters will be evaluated during screening and daily, to include the following:

• Complete Blood Count (WBC, RBC(red blood cell count), Hematocrit, Hemoglobin, MCV (mean corpuscular volume), Platelet Count)

• PT(prothrombin time)/INR (international normalized ratio) Baseline and post study

• Serum/Urine hCG ( human chorionic gonadotropin)baseline and predose

• Activated Partial Thromboplastin Time (aPTT)

Clinical Adverse Events

Clinical Adverse Events will be monitored throughout the study. However, such events are not anticipated during this trial due to the low systemic exposure of the test article being administered. However, local side effects of intranasal heparin, such as epistaxis or nasal congestion may result.

For any abnormal lab values, test subjects will be evaluated for any sign and symptoms, and labs will be redrawn, until stabilized or returned to baseline. Subjects will be referred to the primary physician for any continued care required.

Study Design

• Study Type: Interventional
• Actual Enrollment: 6 participants
• Allocation: N/A
• Intervention Model: Sequential Assignment
• Intervention Model Description: This study will evaluate the acute and multi-day (14 days) tolerability of intranasally administered heparin. Two doses will be tested in the acute phase: 1000 U/day, then 2000 U/day. In the multi-day phase, the highest tolerated dose from the acute phase will be tested over a 14-day period of daily self-administration.This study will evaluate the acute and multi-day (14 days) tolerability of intranasally administered heparin. Two doses will be tested in the acute phase: 1000 U/day, then 2000 U/day. In the multi-day phase, the highest tolerated dose from the acute phase will be tested over a 14-day period of daily self-administration.
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Intranasal Heparin Tolerability Study
• Actual Study Start Date: Oct 9, 2020
• Actual Primary Completion Date: Nov 18, 2020
• Actual Study Completion Date: Nov 18, 2020

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Experimental Arm Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records.

Drug: Intranasal heparin sodium (porcine); Intranasal heparin sodium; Other Names: NDC (National Drug Code) 0409-2721-30 NDC 0409-2723-01

Outcome Measures

Primary Outcome Measures

1. Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1 [24 hours after a 1000 U intranasal dose of heparin]

   A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin collected 24 hours after a 1000 U intranasal dose of heparin

2. Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2 [24 hours after 2000 U dose intranasal heparin]

   A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin collected 24 hours after a 2000 U intranasal dose of heparin

3. Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14 [Day 14, chronic phase]

   A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin obtained immediately after the 14 consecutive day of daily 2000 U dose of intranasal heparin

4. Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15 [24 hours after the last 2000 U dose of the chronic phase]

   A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin obtained 24 hours after the 14 consecutive day of daily 2000 U dose of intranasal heparin

5. Percent Change in Platelet Count From Pre-dose Baseline [Pre-dose baseline, Day 14 chronic phase]

   Indicative of heparin-induced thrombocytopenia, a serious adverse side effect of systemically bioavailable heparin, measured immediately after the last 2000 U intranasal dose of the chronic phase.

6. Number of Incidents of Epistaxis, Acute Phase [Day 0 through Day 2, acute phase]

   Number of incidents of blood coming from the nose during the acute phase

7. Number of Incidents of Epistaxis, Chronic Phase [Day 1 through Day 15, chronic phase]

   Blood coming from the nose or pink tinged nasal secretions

8. Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14 [Day 14, Chronic Phase]

   Abnormally low platelet counts indicative of heparin-induced thrombocytopenia, a serious adverse side effect of systemically bioavailable heparin, measured immediately after the last 2000 U intranasal dose of the chronic phase.

Secondary Outcome Measures

1. Other Adverse Effects, Acute Phase [Day 0 through Day 2, acute phase]

   Reports of mild, short-lived nasal irritation immediately after administration including mild burning sensation

2. Other Adverse Effects, Chronic Phase [Day 1 through Day 15, chronic phase]

   Reports of mild, short-lived nasal irritation immediately after administration including mild burning sensation, itchiness or sneezing

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Normal, healthy adults aged 18 to 65 years

Exclusion Criteria:

• Allergy to Heparin

• Currently taking any prescription blood thinners or anti-coagulants, or currently taking any intranasal medication

• Known history of anemia, thrombocytopenia, or other blood disorder

• Autoimmune disorders

• Known history of Neurologic/Psychiatric disorders

• Report of an active infection

• Subject is pregnant or breast-feeding, or is expecting to conceive during the study.

NOTE: Subjects will be instructed to abstain from alcohol for the duration of the study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The University of Mississippi National Center for Natural Products Research	University	Mississippi	United States	38677-1848

Sponsors and Collaborators

• Joshua Sharp

Investigators

• Principal Investigator: Bill Gurley, PhD, University of Mississippi Medical Center

Study Documents (Full-Text)

• Study Protocol - Sep 1, 2020

More Information

Publications

• Tandon R, Sharp JS, Zhang F, Pomin VH, Ashpole NM, Mitra D, Jin W, Liu H, Sharma P, Linhardt RJ. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives. bioRxiv. 2020 Jul 28. pii: 2020.06.08.140236. doi: 10.1101/2020.06.08.140236. Update in: J Virol. 2021 Jan 13;95(3):.

• Responsible Party: Joshua Sharp, Associate Professor, University of Mississippi, Oxford
• ClinicalTrials.gov Identifier: NCT04490239
• Other Study ID Numbers: Intranasal Heparin
• First Posted: Jul 29, 2020
• Last Update Posted: Apr 30, 2021
• Last Verified: Apr 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Heparin; Calcium heparin

Study Results

Participant Flow

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Period Title: 1000 U Acute (One Dose, Day 1)
STARTED	6
COMPLETED	6
NOT COMPLETED	0
Period Title: 1000 U Acute (One Dose, Day 1)
STARTED	6
COMPLETED	6
NOT COMPLETED	0
Period Title: 1000 U Acute (One Dose, Day 1)
STARTED	6
COMPLETED	6
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Overall Participants	6
Age (Count of Participants)
<=18 years	1 16.7%
Between 18 and 65 years	5 83.3%
>=65 years	0 0%
Age (years) [Mean (Full Range) ]
Mean (Full Range) [years]	31
Sex: Female, Male (Count of Participants)
Female	3 50%
Male	3 50%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	6 100%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	6 100%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	6 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1
Description	A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin collected 24 hours after a 1000 U intranasal dose of heparin
Time Frame	24 hours after a 1000 U intranasal dose of heparin

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
participants with normal aPTT (24-33 sec)	6 100%
participants with abnormal aPTT (<24 sec or >33 sec)	0 0%

2. Primary Outcome

Title	Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2
Description	A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin collected 24 hours after a 2000 U intranasal dose of heparin
Time Frame	24 hours after 2000 U dose intranasal heparin

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Participants with normal aPTT (24-33 sec)	6 100%
Participants with abnormal aPTT (<24 sec or >33 sec)	0 0%

3. Primary Outcome

Title	Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14
Description	A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin obtained immediately after the 14 consecutive day of daily 2000 U dose of intranasal heparin
Time Frame	Day 14, chronic phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Participants with normal aPTT (24-33 sec)	6 100%
Participants with abnormal aPTT (<24 sec or >33 sec)	0 0%

4. Primary Outcome

Title	Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15
Description	A measurement of blood clotting ability; tests for systemic bioavailability of intranasal heparin obtained 24 hours after the 14 consecutive day of daily 2000 U dose of intranasal heparin
Time Frame	24 hours after the last 2000 U dose of the chronic phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Participants with normal aPTT (24-33 sec)	6 100%
Participants with abnormal aPTT (<24 sec or >33 sec)	0 0%

5. Primary Outcome

Title	Percent Change in Platelet Count From Pre-dose Baseline
Description	Indicative of heparin-induced thrombocytopenia, a serious adverse side effect of systemically bioavailable heparin, measured immediately after the last 2000 U intranasal dose of the chronic phase.
Time Frame	Pre-dose baseline, Day 14 chronic phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Mean (Full Range) [percent change from baseline]	2.2

6. Primary Outcome

Title	Number of Incidents of Epistaxis, Acute Phase
Description	Number of incidents of blood coming from the nose during the acute phase
Time Frame	Day 0 through Day 2, acute phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Number [Reported incidents]	0

7. Primary Outcome

Title	Number of Incidents of Epistaxis, Chronic Phase
Description	Blood coming from the nose or pink tinged nasal secretions
Time Frame	Day 1 through Day 15, chronic phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Number [Reported incidents]	1

8. Primary Outcome

Title	Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14
Description	Abnormally low platelet counts indicative of heparin-induced thrombocytopenia, a serious adverse side effect of systemically bioavailable heparin, measured immediately after the last 2000 U intranasal dose of the chronic phase.
Time Frame	Day 14, Chronic Phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Participants with normal platelet counts (150,000 - 450,000 platelets/uL)	6 100%
Participants with abnormal platelet counts (<150,000 or >450,000 platelets/uL)	0 0%

9. Secondary Outcome

Title	Other Adverse Effects, Acute Phase
Description	Reports of mild, short-lived nasal irritation immediately after administration including mild burning sensation
Time Frame	Day 0 through Day 2, acute phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Number [Reported incidents]	2

10. Secondary Outcome

Title	Other Adverse Effects, Chronic Phase
Description	Reports of mild, short-lived nasal irritation immediately after administration including mild burning sensation, itchiness or sneezing
Time Frame	Day 1 through Day 15, chronic phase

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
Measure Participants	6
Number [Reported incidents]	5

Adverse Events

Time Frame	From date of first dose in acute phase through sixteen days after last dose in chronic phase; 38 days total
Adverse Event Reporting Description	Adverse event collection was obtained by vital sign measurement, INR measurements from blood collection, and subject self-reporting
Arm/Group Title	Experimental Arm
Arm/Group Description	Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL. Acute phase: On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects. Chronic phase: The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records. Intranasal heparin sodium (porcine): Intranasal heparin sodium
All Cause Mortality
	Experimental Arm
	Affected / at Risk (%)	# Events
Total	0/6 (0%)
Serious Adverse Events
	Experimental Arm
	Affected / at Risk (%)	# Events
Total	0/6 (0%)
Other (Not Including Serious) Adverse Events
	Experimental Arm
	Affected / at Risk (%)	# Events
Total	3/6 (50%)
Respiratory, thoracic and mediastinal disorders
Mild nasal irritation lasting less than 1 min after administration	2/6 (33.3%)	7
Epistaxis	1/6 (16.7%)	2

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.